

Filed on behalf of: Aventis Pharma S.A.

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN LABORATORIES LIMITED

Petitioner,

v.

AVENTIS PHARMA S.A.

Patent Owner.

Case IPR2016-00712

U.S. Patent No. 8,927,592

AVENTIS PHARMA S.A.
UPDATE TO MANDATORY NOTICES – 37 C.F.R. § 42.8(a)(3)

Pursuant to 37 C.F.R. § 42.8(a)(3), Aventis Pharma S.A. (the “Patent Owner”) submits the following update to its April 5, 2016 Mandatory Notices (Paper No. 6).

Real Party-In-Interest (37 C.F.R. § 42.8 (b)(1)):

The real party-in-interest information has not changed.

Related Matters (37 C.F.R. § 42.8 (b)(2)):

The related matters information has not changed.

Designation of Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)):

The lead counsel information has not changed.

The Patent Owner hereby notifies the Board that it is adding Daniel J. Minion (Registration No. 53,329) as additional back-up counsel. All other counsel information remains the same.

Additional back-up counsel:

Daniel J. Minion
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel: (212) 218-2100
dminion@fchs.com

Service Information (37 C.F.R. § 42.8(b)(4)):

The service information has not changed.

October 14, 2016

Respectfully submitted,

/Dominick A. Conde/

Dominick A. Conde (Reg. No. 33,856)
Lead Counsel for Patent Owner
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
(212) 218-2100

CERTIFICATE OF SERVICE

I certify that a copy of the UPDATE TO MANDATORY NOTICES – 37 C.F.R. § 42.8(a)(3) was served on October 14, 2016 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

sparmelee@wsgr.com

mrosato@wsgr.com

jmills@wsgr.com

October 14, 2016

Respectfully submitted,

/Dominick A. Conde/

Dominick A. Conde (Reg. No. 33,856)
FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel: (212) 218-2100